Physician profile
Alexander Epelbaum
NPI 1487673612
$7,222.62
in general payments reported to CMS, 2019-2025
35 companies · $2,201 in 2025
The $2,201 reported for 2025 was more than what 82% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,158 · 2020: $265 · 2021: $276 · 2022: $837 · 2023: $1,527 · 2024: $959 · 2025: $2,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,587 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,586.77 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $1,221.37 | 2021-2025 | Aquabeam Robotic System, Aquabeam System |
| Astellas Pharma US INC | $1,102.81 | 2019-2025 | Xtandi, Myrbetriq |
| Janssen Biotech, INC. | $864.47 | 2019-2025 | Erleada, Akeega |
| Sumitomo Pharma America, INC. | $430.84 | 2023-2025 | Orgovyx, Gemtesa |
| Teleflex LLC | $361.51 | 2020-2025 | Urolift, Barrigel |
| Urogen Pharma, INC. | $324.82 | 2023-2025 | Jelmyto |
| Boston Scientific Corporation | $300.92 | 2023-2025 | Axonics |
| Bayer Healthcare Pharmaceuticals INC. | $241.98 | 2019-2025 | |
| Pfizer INC. | $217.79 | 2019-2025 | |
| Palette Life Sciences, INC. | $200.40 | 2022-2023 | |
| Endo Pharmaceuticals INC. | $170.22 | 2019-2024 | Xiaflex, Aveed, Edex |
| Ferring Pharmaceuticals INC. | $164.83 | 2019-2025 | Adstiladrin |
| Abbvie INC. | $157.17 | 2019-2022 | |
| Endo USA, INC. | $157.15 | 2024-2025 | Xiaflex, Aveed |
| Myovant Sciences INC. | $142.36 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $115.71 | 2021-2025 | Xyosted |
| Tolmar, INC. | $115.55 | 2023-2025 | Jatenzo |
| Olympus America INC. | $95.35 | 2025 | Itind System |
| Dendreon Pharmaceuticals LLC | $89.52 | 2022-2025 | Provenge |
| Progenics Pharmaceuticals, INC. | $87.66 | 2023-2025 | Pylarify |
| Merck Sharp & Dohme LLC | $87.50 | 2019-2022 | |
| C. R. Bard, INC. & Subsidiaries | $86.99 | 2019 | |
| Urovant Sciences INC | $67.18 | 2021-2022 | |
| Ge Healthcare | $61.73 | 2023 | |
| Immunitybio, INC. | $60.30 | 2025 | |
| Rochester Medical Corporation | $59.53 | 2019-2020 | |
| Accord Healthcare, INC. | $41.96 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $41.31 | 2025 | |
| Shionogi INC | $25.00 | 2022 | |
| Myriad Genetic Laboratories, INC. | $23.96 | 2024 | Prolaris |
| Zyla Life Sciences, INC. | $22.10 | 2019 | |
| Coloplast Corp | $22.07 | 2023 | Speedicath |
| Emd Serono, INC. | $21.84 | 2019 | |
| Photocure INC | $20.69 | 2025 | Cysview |
| Medtronic, INC. | $18.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Epelbaum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.